2:39 PM
Jul 10, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Liver cancer

In vitro, cell culture and mouse studies identified a SALL4-derived peptide inhibitor of the SALL4-RBBP4 interaction that could help treat hepatocellular carcinoma (HCC). Chemical synthesis and in vitro testing of analogs of a SALL4-derived peptide yielded a compound that inhibited SALL4-RBBP4 binding with an...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >